福尔菲里
伊立替康
奥沙利铂
医学
养生
福克斯
丸(消化)
氟尿嘧啶
化疗
结直肠癌
内科学
肿瘤科
外科
癌症
作者
Naomi Uemura,Yasuhide Yamada
出处
期刊:PubMed
日期:2006-07-01
卷期号:33 (7): 904-6
摘要
Irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and Leucovorin (LV) became the standard first-line chemotherapy for colorectal cancer in the U.S. and Europe in 2000, largely owing to the results of controlled randomized phase III trials of 5-FU/LV with or without CPT-11. One of the regimens for CPT-11 plus infusional 5-FU/LV therapy is the FOLFIRI regimen. This regimen consists of CPT-11 180 mg/m(2) as a 90-min infusion on day 1 and l-LV 200 mg/m(2) as a 2-h infusion during CPT-11, immediately followed by a bolus dose of 5-FU 400 mg/m(2) and a 46-h continuous infusion of 2,400 mg/m(2) every 2 weeks. FOLFIRI, as well as oxaliplatin/5-FU/LV therapy (FOLFOX), is an internationally accepted standard chemotherapy for metastatic colorectal cancer. Safe use of this effective regimen requires adequate supportive therapy in Japan, as well as in Western countries.
科研通智能强力驱动
Strongly Powered by AbleSci AI